Storys zum Thema Krebs
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- 3mehr
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrThe world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
mehrDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehr- 2
Free Access to Cancer Research Services - canSERV 1st Call for Proposals
mehr Free Access to Cancer Research Services - canSERV 1st Call for Proposals
Ein DokumentmehrAccord Healthcare marks World Cancer Day 2023 appearing in ITN Business news-style programme Working Together: To Tackle Cancer
London (ots/PRNewswire) - Accord Healthcare (Accord), one of Europe's fastest growing pharmaceutical companies, marks World Cancer Day 2023 today by taking part in news-style programme for ITN Business alongside other partners from industry and the patient community to raise awareness of the importance of working ...
mehrIEVA (Independent European Vape Alliance)
World Cancer Day - Decrease smoking rates with reduced-risk alternatives
Brussels (ots) - 19.7 percent of the EU population are daily smokers. [1] 700,000 people in the EU die each year as a result of smoking and every second smoker dies on average 14 years prematurely. [2] Smoking is the leading cause of preventable cancer, with 27 percent of all cancers attributed to tobacco. [3] The examples of Great Britain (smoking rate: 13.8 percent) ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
mehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrTechnische Universität München
New X-ray technology can improve Covid-19 diagnosis
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Images: https://mediatum.ub.tum.de/1692790 NEWS RELEASE New X-ray technology can improve Covid-19 diagnosis Patient study demonstrates benefits of dark-field X-ray technology A research team at the Technical University of Munich (TUM) has, for the first time, produced dark-field X-ray images of ...
mehrTechnische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
mehrHearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...
mehrKlinik für Prostata-Therapie Heidelberg
Focal therapy for prostate cancer: Reliable diagnosis leads to gentle treatment
mehrLandscape of molecular contacts: How the coronavirus SARS-CoV-2 communicates with human cells
mehr- 2
OPTIMA announces AstraZeneca and MUTABOR as official partners
mehr DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...
mehrBIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY
Lausanne, Switzerland (ots) - · Currently approved Antibody-Drug Conjugates (ADCs) are large molecules (150 kDa) composed of an antibody, a cytotoxic payload, and a linker connecting the two precedent elements · Debiopharm has launched an ADC Innovation Challenge to a pool of international “problem Solvers” ...
mehrTechnische Universität München
Improved monitoring of silicone implants
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/aktuelles/alle-meldungen/pressemitteilungen/details/verbessertes-monitoring-von-silikonimplantaten Pictures: https://mediatum.ub.tum.de/1687409 NEWS RELEASE Improved monitoring of silicone implants New algorithm for clinical MRI scanners makes breast ...
mehrcanSERV - EU cluster project provides cancer research services across Europe
CanSERV Providing Cutting Edge Cancer Research Services Across Europe European wide research infrastructures, oncology experts, and patient associations team up to battle cancer Brussels, 15 September 2022: The European canSERV project, aiming to defragment the landscape of ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...
mehrEuropean Inventor Award 2022: Meet the inventors that are shaping our world at virtual event
Munich (ots) - - The winners of the European Patent Office’s annual innovation prize will be revealed at a ceremony on 21 June 2022 at 12:00 CEST held in an all-new format - Discover the stories of 14 exceptional inventor teams and 4 young innovators from 14 countries - The public is now invited to vote for their favourite inventor to win the Popular Prize at ...
mehr- 3
Sysmex Europe SE and Sysmex Inostics GmbH launch two CE-IVD certified Plasma-SeqSensei™ liquid biopsy kits: Solid Cancer IVD Kit and Breast Cancer IVD Kit
Ein Dokumentmehr Is microplastic carcinogenic?
Graz/Vienna (ots) - The effects of micro- and nanoplastic particles (MNP) in the human body are being investigated in depth for the first time worldwide. From 2022 to 2025, research will be performed at CBmed together with international partners to elucidate potential health effects of microplastics. Every person in developed countries currently ingests an average of five grams of plastics per week - that's as much as a standard credit card. What these micro- and nanoplastic ...
mehrTechnische Universität München
Overcoming resistance of pancreatic cancer to immunotherapies
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37173 High resolution images: https://mediatum.ub.tum.de/1641984 NEWS RELEASE “Inflaming” cold tumors Overcoming resistance of pancreatic cancer to immunotherapies Pancreatic carcinoma is a ...
mehrUniversity of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
mehrIEVA (Independent European Vape Alliance)
Vaping industry underlines the importance of product choice
Brussels (ots) - The Independent European Vape Alliance (IEVA) welcomed the decision of MEPs to recognize tobacco harm reduction as a tool in beating cancer; but remains concerned that the report approved today by the European Parliament leaves the door open to a flavour ban in the EU. The Special Committee on Beating Cancer (BECA) today voted on the amendments and the draft of the Beating Cancer report by Rapporteur ...
mehrCHRISTMAS COMES EARLY FOR CHILDREN WITH CANCER COURTESY OF PM-INTERNATIONAL MALAYSIA
mehr